Orphazyme A/S (ORPH)

$ 4.6
-0.09 -1.92%
-
Symbol ORPH
Price $ 4.6
Beta 0.640
Volume Avg. 11.07M
Market Cap 0.17B
Shares () -
52 Week Range 3.95-77.77
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -144.20% Strong Sell
ROA -113.40% Strong Sell
Operating Margin -
Debt / Equity 156.67% Buy
P/E -
P/B 3.49 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

About


Ms. Kim Stratton
Healthcare
Biotechnology
Nasdaq Global Select

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Its lead candidate is the Arimoclomol, which is in clinical development for four orphan diseases, including Niemann-Pick disease type C, Gaucher disease, sporadic inclusion body myositis, and amyotrophic lateral sclerosis. The company was founded in 2009 and is headquartered in Copenhagen, Denmark.